247 related articles for article (PubMed ID: 33416146)
1. Regulatory role of DEPTOR‑mediated cellular autophagy and mitochondrial reactive oxygen species in angiogenesis in multiple myeloma.
Wang J; Chen J; Qiu D; Zeng Z
Int J Mol Med; 2021 Feb; 47(2):643-658. PubMed ID: 33416146
[TBL] [Abstract][Full Text] [Related]
2. DEPTOR Deficiency-Mediated mTORc1 Hyperactivation in Vascular Endothelial Cells Promotes Angiogenesis.
Ding Y; Shan L; Nai W; Lin X; Zhou L; Dong X; Wu H; Xiao M; Zhou X; Wang L; Li T; Fu Y; Lin Y; Jia C; Dai M; Bai X
Cell Physiol Biochem; 2018; 46(2):520-531. PubMed ID: 29614494
[TBL] [Abstract][Full Text] [Related]
3. Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis.
Giuliani N; Colla S; Lazzaretti M; Sala R; Roti G; Mancini C; Bonomini S; Lunghi P; Hojden M; Genestreti G; Svaldi M; Coser P; Fattori PP; Sammarelli G; Gazzola GC; Bataille R; Almici C; Caramatti C; Mangoni L; Rizzoli V
Blood; 2003 Jul; 102(2):638-45. PubMed ID: 12649156
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of DEPTOR induces apoptosis, increases chemosensitivity to doxorubicin and suppresses autophagy in RPMI-8226 human multiple myeloma cells in vitro.
Zhang H; Chen J; Zeng Z; Que W; Zhou L
Int J Mol Med; 2013 May; 31(5):1127-34. PubMed ID: 23503641
[TBL] [Abstract][Full Text] [Related]
5. Microvesicles shed from bortezomib-treated or lenalidomide-treated human myeloma cells inhibit angiogenesis in vitro.
Guo HM; Sun L; Yang L; Liu XJ; Nie ZY; Luo JM
Oncol Rep; 2018 Jun; 39(6):2873-2880. PubMed ID: 29693175
[TBL] [Abstract][Full Text] [Related]
6. A Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor Cytotoxicity.
Vega MI; Shi Y; Frost P; Huerta-Yepez S; Antonio-Andres G; Hernandez-Pando R; Lee J; Jung ME; Gera JF; Lichtenstein A
Mol Cancer Ther; 2019 Oct; 18(10):1822-1831. PubMed ID: 31395691
[TBL] [Abstract][Full Text] [Related]
7. Fucoidan inhibits angiogenesis induced by multiple myeloma cells.
Liu F; Luo G; Xiao Q; Chen L; Luo X; Lv J; Chen L
Oncol Rep; 2016 Oct; 36(4):1963-72. PubMed ID: 27498597
[TBL] [Abstract][Full Text] [Related]
8. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
[TBL] [Abstract][Full Text] [Related]
9. Deptor transcriptionally regulates endoplasmic reticulum homeostasis in multiple myeloma cells.
Catena V; Bruno T; De Nicola F; Goeman F; Pallocca M; Iezzi S; Sorino C; Cigliana G; Floridi A; Blandino G; Fanciulli M
Oncotarget; 2016 Oct; 7(43):70546-70558. PubMed ID: 27655709
[TBL] [Abstract][Full Text] [Related]
10. Absence of clinical prognostic value of vascular endothelial growth factor and microvessel density in multiple myeloma.
Choi JH; Ahn MJ; Jang SJ; Park CK; Park YW; Oh HS; Lee YY; Choi IY; Kim IS
Int J Hematol; 2002 Dec; 76(5):460-4. PubMed ID: 12512841
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma.
De Luisi A; Ferrucci A; Coluccia AM; Ria R; Moschetta M; de Luca E; Pieroni L; Maffia M; Urbani A; Di Pietro G; Guarini A; Ranieri G; Ditonno P; Berardi S; Caivano A; Basile A; Cascavilla N; Capalbo S; Quarta G; Dammacco F; Ribatti D; Vacca A
Clin Cancer Res; 2011 Apr; 17(7):1935-46. PubMed ID: 21307145
[TBL] [Abstract][Full Text] [Related]
12. DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma.
Quwaider D; Corchete LA; Misiewicz-Krzeminska I; Sarasquete ME; Pérez JJ; Krzeminski P; Puig N; Mateos MV; García-Sanz R; Herrero AB; Gutiérrez NC
J Hematol Oncol; 2017 Apr; 10(1):92. PubMed ID: 28420429
[TBL] [Abstract][Full Text] [Related]
13. VEGF-A promotes angiogenesis after acute myocardial infarction through increasing ROS production and enhancing ER stress-mediated autophagy.
Zou J; Fei Q; Xiao H; Wang H; Liu K; Liu M; Zhang H; Xiao X; Wang K; Wang N
J Cell Physiol; 2019 Aug; 234(10):17690-17703. PubMed ID: 30793306
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells.
Shi Y; Daniels-Wells TR; Frost P; Lee J; Finn RS; Bardeleben C; Penichet ML; Jung ME; Gera J; Lichtenstein A
Cancer Res; 2016 Oct; 76(19):5822-5831. PubMed ID: 27530328
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
Roccaro AM; Hideshima T; Raje N; Kumar S; Ishitsuka K; Yasui H; Shiraishi N; Ribatti D; Nico B; Vacca A; Dammacco F; Richardson PG; Anderson KC
Cancer Res; 2006 Jan; 66(1):184-91. PubMed ID: 16397231
[TBL] [Abstract][Full Text] [Related]
16. JunB is a key regulator of multiple myeloma bone marrow angiogenesis.
Fan F; Malvestiti S; Vallet S; Lind J; Garcia-Manteiga JM; Morelli E; Jiang Q; Seckinger A; Hose D; Goldschmidt H; Stadlbauer A; Sun C; Mei H; Pecherstorfer M; Bakiri L; Wagner EF; Tonon G; Sattler M; Hu Y; Tassone P; Jaeger D; Podar K
Leukemia; 2021 Dec; 35(12):3509-3525. PubMed ID: 34007044
[TBL] [Abstract][Full Text] [Related]
17. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.
Mileshkin L; Honemann D; Gambell P; Trivett M; Hayakawa Y; Smyth M; Beshay V; Ritchie D; Simmons P; Milner AD; Zeldis JB; Prince HM
Haematologica; 2007 Aug; 92(8):1075-82. PubMed ID: 17640854
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis in multiple myeloma.
Rajkumar SV; Kyle RA
Semin Oncol; 2001 Dec; 28(6):560-4. PubMed ID: 11740809
[TBL] [Abstract][Full Text] [Related]
19. HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
Ria R; Catacchio I; Berardi S; De Luisi A; Caivano A; Piccoli C; Ruggieri V; Frassanito MA; Ribatti D; Nico B; Annese T; Ruggieri S; Guarini A; Minoia C; Ditonno P; Angelucci E; Derudas D; Moschetta M; Dammacco F; Vacca A
Clin Cancer Res; 2014 Feb; 20(4):847-58. PubMed ID: 24297864
[TBL] [Abstract][Full Text] [Related]
20. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]